Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by eyeNteeon Aug 20, 2013 7:18pm
226 Views
Post# 21684832

RE:VPT

RE:VPTVPT is on the right track and soon enough we will be there...                                                                                                                                                                                                                                
According to the American Society of Echocardiography Working Group, Quantification of Right Ventricle (RV) function is needed under MOST circumstances. “Although multiple methods for quantitative echocardiographic RV assessment have been described, in clinical practice assessment of RV structure and function remains mostly qualitative. Nevertheless, numerous studies have recently emphasized the importance of RV function in the prognosis of a variety of cardiopulmonary diseases suggesting that more routine quantification of RV function is warranted under most clinical circumstances.”
 
Echocardiographic measurements of size and estimates of function of the left ventricle are widely used clinically, and are known to be of diagnostic as well as prognostic importance in patients with cardiac disease. It is widely accepted that evaluation of the RV is just as important. However, assessment of the RV is challenging, as the 2-dimensional (2D) approaches to the evaluation of size and function of the RV fail to give accurate results. The RV needs to be analyzed or quantified which is difficult to achieve due to the complex shape of the RV.  This is predominantly due to the complex anatomy of the RV, not resembling any known geometrical shape. 3D Ultrasound presents its own unique challenges for RV assessment that have yet to be overcome by technology. VMS has emerged as the tool of choice for not only ease of use, but for accurate and reproducible RV analysis with 2D Echo.
      
Bullboard Posts